The board of directors of Ascelia Pharma AB (“Ascelia”) has on February 21, 2023 resolved to convert 54,500 series C shares into ordinary shares for delivery of shares to participants in the long-term incentive program in the form of a performance-based share saving program that was adopted at the annual general meeting held on 14 November 2019 (“LTI 2019”).
The board of directors of Ascelia has, in accordance with the provisions of LTI 2019, resolved to convert 54,500 series C shares for allotment of 54,500 ordinary shares to the participants in LTI 2019, where 24,500 ordinary shares were allotted to the CEO of Ascelia and 30,000 ordinary shares were allotted to other participants. In total, five participants have been allotted ordinary shares in LTI 2019.
The number of outstanding shares in Ascelia, after the registration of the above-mentioned conversion of series C shares into ordinary shares, amounts to a total of 34,871,177 shares, of which 33,722,762 are ordinary shares with one vote each and 1,148,415 are series C shares with 1/10 vote each. All series C shares are held by Ascelia. The total number of votes in Ascelia amounts to 33,837,603.5.